Transcept Pharmaceuticals Receives Complete Response Letter From FDA On Intermezzo(R) New Drug Application
October 30th, 2009 | No Comments | Posted in Medical Information, Sleep / Sleep Disorders / Insomnia
Transcept Pharmaceuticals (Nasdaq: TSPT) announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). The NDA, submitted by Transcept in September 2008, seeks approval to market Intermezzo® for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
Tags: Insomnia
Sleeping problems
Insomnia information
Sleepin 